Re-link HCV in Substance-Use Telemedicine Program
NCT06349902
Summary
This is an observational, retrospective \& prospective cohort study. The retrospective element of the study is a chart review to identify people with diagnosed but untreated HCV and re-link them to care. The observational prospective cohort element of the study will examine the HCV linkage to care, treatment initiation, treatment completion \& cure rates of these HCV clients achieved through this chart review and re-linking approach.
Eligibility
Inclusion Criteria: For the retrospective chart review element of the study, inclusion criteria includes anyone who had a telemedicine visit at the community based substance use telemedicine program between January 1st 2023 and December 31st 2024. For the prospective cohort element of the study, the inclusion criteria are listed below: Aged ≥18. Ability and willingness of the participant to provide informed consent. Having a positive HCV RNA laboratory result and lacking a sufficient previous course of DAA treatment. Exclusion Criteria: For the retrospective chart review element of the study, exclusion criteria is: a consent directive to restrict access to their OLIS record. For the prospective cohort study, exclusion criteria is an inability or unwillingness of the participant to provide informed consent. \-
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06349902